The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.
On October 16, 2023, the FDA announced a plan entitled “Enhancing Adoption of Innovative Clinical Trial Approaches,” which will lead up to a March 2024 conference to conclude the future steps in making clinical trials more effective and useful, emphasizing regulatory and compliance considerations, patient-centricity and trial infrastructure and organization culture in addition to the adoption of digital health technologies (DHT).
The FDA acknowledged more than a decade ago that the present clinical trial system needs changes and has suggested several novel approaches to design clinical trials, including risk-based and proportionate measures throughout a clinical trial's lifecycle (data collecting, monitoring, and quality management).1,2 This method encourages scientists to prioritize participant safety and data integrity in data and clinical trial processes. It further helps investigators to focus on gathering and evaluating essential trial data and encourages sponsors to be proactive about trial quality. Quality considerations include trial features that protect participants, ensure trial findings, and inform decision-making.
Early attention to these aspects helps design trials efficiently, reducing delays from excessive complexity and burdens. Since the FDA has opened a portal to receive stakeholders' comments and specific suggestions to reduce redundant testing that can reduce the cost of development of drugs, particularly biologics, I am submitting a detailed document describing why the FDA should take decisive action—albeit within the limits of the regulations—to state that clinical efficacy testing is not necessary. This statement is needed to encourage developers with fewer resources to enter the field by removing their fear of ending up with a cost of hundreds of millions of dollars. Given below are my arguments that the stakeholders can use, along with their own, to submit as many comments as possible to the FDA portal:
Several studies have supported the arguments presented above, including a meta-analysis of studies in more than 12,000 patients; the fact that the European Medicines Agency (EMA) or FDA have never requested withdrawal or recall of any biosimilar, none of the over 200 trials for which results are reported showed any difference in comparative efficacy.3 PubMed database lists over 1,200 publications reporting CCS for biosimilars and none noting clinically meaningful differences. Of most tremendous significance is a recent preprint article by former EMA associates summarizing 33 monoclonal antibodies and 3 fusion proteins filings from July 2012 to November 2022 and suggested that analytical, functional, and pharmacokinetic test, including immunogenicity data, is sufficient to establish biosimilarity.
In summary, the CCSs are redundant, which should be made a strong point in the suggestions made to the FDA. An example of how the CCSs are approved is given by the Medicines and Healthcare Regulatory Agency (MHRA) of the United Kingdom, which had updated its biosimilar guideline to state:
“Although each biosimilar development needs to be evaluated on a case-by-case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach. Therefore, a well-argued justification for the absence of an efficacy trial should be appended to CTD Module 1 of the submitted application.”
I recommend that the FDA concur with MHRA and harmonize the biosimilar approval guidelines. It is time for the stakeholders to make their voices heard.
Reference
1. Cohen D. FDA official: "clinical trial system is broken". BMJ. 2013;347:f6980. doi:10.1136/bmj.f6980
2. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70. doi:10.1056/NEJMra1510062
3. Bloomfield D, D'Andrea E, Nagar S, Kesselheim A. Characteristics of clinical trials evaluating biosimilars in the treatment of cancer: a systematic review and meta-analysis. JAMA Oncol. 2022;8(4):537-545. doi:10.1001/jamaoncol.2021.7230
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.